TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Not Specified
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

VYNE Therapeutics and Yarrow Bioscience have agreed to merge in an all-stock transaction, with Yarrow becoming the combined company. The merger will focus on advancing YB-101, a potential first-in-class antibody for treating Graves' disease and thyroid eye disease, supported by approximately $200 million in pre-closing private financings.

Insights
VYNE   neutral

Executing strategic alternative to maximize shareholder value, but will significantly reduce ownership in combined entity